M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC

Introduction Non-small cell lung cancer (NSCLC), which accounts for >85% of all lung cancers, is the most common solid malignant tumor, with high morbidity and mortality worldwide. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment is widely used clinically because th...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaofeng Zhi MMed, Silin Liu MMed, Xuefei Chang MMed, Wanxian Guan MMed, Ronggang Li MMed, Qiongru Liu BSc, Jiaqing Chen MSc, Jie Ling BSc, Xulin Zhao BSc, Aibin Liu MD, Jiarong Chen MD, Xin Zhang MD, Yanming Huang MMed
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/10732748251342685
Tags: Add Tag
No Tags, Be the first to tag this record!